A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination with Immune Therapeutic Agents in Adult Subjects with Advanced Solid Tumors
A study for patients with advanced solid tumors using study drug MEDI0562
Sponsor: MedImmune
Enrolling: Male and Female Patients
IRB Number: AAAQ7663
U.S. Govt. ID: NCT02705482
Contact: Richard Carvajal, MD: 646-317-6344 / rdc2150@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to determine the best dose of MEDI0562 in combination with durvalumab, and MEDI0562 in combination with tremelimumab, that is safe and tolerable in subjects with advanced solid tumors.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with a solid tumor? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Richard Carvajal, MD
rdc2150@cumc.columbia.edu
646-317-6344
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE